文献速递药物不良反应与药物警戒特殊人群用药

双氯芬酸心血管风险最小化措施对肌肉骨骼疾病镇痛药使用的影响

Impact of diclofenac risk minimization measures addressing cardiovascular risk on analgesic use in musculoskeletal disorders.
PubMed 文献 · Br J Clin Pharmacol · 2025-06-16

研究利用英国CPRD GOLD初级保健数据,纳入2010-2019年新诊断肌肉骨骼疾病患者1 798 885例,评估2013年欧洲双氯芬酸心血管风险最小化措施(RMMs)对镇痛药使用的影响。结果显示双氯芬酸起始使用在RMMs前已呈下降趋势,RMMs后2个队列出现进一步即刻下降(从-0.9%至-1.6%),但下降幅度与患者心血管风险无关;从诊断到镇痛治疗的时间在RMMs后延长,慢性关节炎性疾病患者中位时间从4.2个月增至7.6个月(95%CI 4.0-4.5和7.4-7.8)。

要点

  • RMMs后双氯芬酸起始使用进一步下降,但降幅与心血管风险分层无关。
  • 有禁忌症(既往心血管事件)患者仍持续使用全身性双氯芬酸,提示RMMs影响有限。
  • RMMs后诊断至镇痛治疗时间延长,慢性关节炎性疾病患者中位时间从4.2个月增至7.6个月。

核心结论

  • 双氯芬酸起始使用的下降与患者心血管风险无关,有禁忌症患者仍持续使用全身性双氯芬酸,提示RMMs影响有限。
  • 诊断至镇痛治疗时间延长,提示镇痛药处方实践发生更广泛变化。

研究设计与样本

  • 基于英国CPRD GOLD初级保健数据的队列研究,纳入2010-2019年新诊断肌肉骨骼疾病患者共1 798 885例。
  • 按诊断分为4个队列:急性(炎症性)肌肉骨骼疾病、慢性关节炎性疾病、继发性关节炎性疾病或其他疼痛性疾病。
  • 采用中断时间序列和生存分析评估RMMs影响,并按心血管风险分层:无危险因素或禁忌症、至少1个危险因素、至少1个禁忌症(既往心血管事件)。

主要发现

  • 超过28%的患者至少有1个心血管危险因素,超过7%的患者至少有1个双氯芬酸禁忌症。
  • 双氯芬酸起始使用在RMMs前已下降,RMMs后2个队列出现进一步即刻下降(从-0.9%至-1.6%)。
  • RMMs的影响在不同心血管风险分层间无实质性差异。
  • RMMs实施后诊断至镇痛治疗时间延长,慢性关节炎性疾病患者中位时间从4.2个月增至7.6个月(95%CI 4.0-4.5和7.4-7.8)。

临床怎么用

  • 临床应关注有心血管禁忌症患者仍持续使用全身性双氯芬酸的情况,加强处方审核。
  • 对肌肉骨骼疾病患者启动镇痛治疗时,需结合心血管风险评估选择药物。
  • RMMs后治疗启动时间延长,提示需关注患者疼痛管理的及时性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In 2013, risk minimization measures (RMMs) were introduced in Europe to address the increased cardiovascular risk linked to diclofenac. This study aimed to assess the impact of those RMMs on analgesic use. METHODS: Primary care data from CPRD GOLD (UK) were used. Patients newly diagnosed with musculoskeletal disorders during 2010-2019 were categorized into 4 cohorts, according to their diagnosis: acute (inflammatory) musculoskeletal conditions, chronic arthritic conditions, secondary arthritic conditions, or other painful conditions. The impact of the RMMs was studied using interrupted time series and survival analyses. Analyses were stratified by cardiovascular risk: (i) no risk factors or contraindications mentioned by RMMs; (ii) at least 1 risk factor; and (iii) at least 1 contraindication (prior cardiovascular events). RESULTS: In total, 1 798 885 patients were included, with >28% having at least 1 cardiovascular risk factor and >7% having at least 1 contraindication for diclofenac. Initiation of diclofenac was already decreasing before the RMMs, but the RMMs were associated with a further immediate decrease in 2 cohorts (from -0.9 to -1.6%). No substantial difference in impact was observed depending on cardiovascular risk. The time from diagnosis to analgesic treatment increased after RMMs implementation, especially in patients with chronic arthritic conditions: median time increased from 4.2 to 7.6 months [95% confidence interval 4.0-4.5 and 7.4-7.8, respectively]. CONCLUSION: The observed decrease of diclofenac initiation was unrelated to patients' cardiovascular risk. Continued prescribing of systemic diclofenac to patients with contraindications suggests limited impact of RMMs. Increased time from diagnosis to analgesic treatment suggests broader changes in analgesic prescribing practices.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lasys T, Santa-Ana-Tellez Y, Siiskonen SJ, et al. Impact of diclofenac risk minimization measures addressing cardiovascular risk on analgesic use in musculoskeletal disorders. Br J Clin Pharmacol. 2025. PMID: 40523664. doi:10.1002/bcp.70142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。